再潅流傷害(Reperfusion Injury):世界の治験レビュー(2015年上半期版)

◆英語タイトル:Reperfusion Injury Global Clinical Trials Review, H1, 2015
◆商品コード:GDHC2605CTIDB
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月27日
◆ページ数:86
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥555,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥832,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界における再潅流傷害(Reperfusion Injury) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - 再潅流傷害(Reperfusion Injury)
  - 当レポートの概要
・再潅流傷害(Reperfusion Injury):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Reperfusion Injury Global Clinical Trials Review, H1, 2015

Summary

GlobalData’s clinical trial report, “Reperfusion Injury Global Clinical Trials Review, H1, 2015″ provides data on the Reperfusion Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Reperfusion Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Reperfusion Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Reperfusion Injury 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Reperfusion Injury to Cardiovascular Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Reperfusion Injury to Cardiovascular Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Reperfusion Injury 24
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Reperfusion Injury Therapeutics Clinical Trials 30
Prominent Drugs 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Ikaria Holdings, Inc. 32
Clinical Trial Overview of Ikaria Holdings, Inc. 32
Stealth Peptides Inc. 33
Clinical Trial Overview of Stealth Peptides Inc. 33
Y’s Therapeutics Co., Ltd. 34
Clinical Trial Overview of Y’s Therapeutics Co., Ltd. 34
Trophos SA 35
Clinical Trial Overview of Trophos SA 35
Takeda Pharmaceutical Company Limited 36
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 36
Prolong Pharmaceuticals 37
Clinical Trial Overview of Prolong Pharmaceuticals 37
NeuroVive Pharmaceutical AB 38
Clinical Trial Overview of NeuroVive Pharmaceutical AB 38
Minapharm Pharmaceuticals & Chemical Industries 39
Clinical Trial Overview of Minapharm Pharmaceuticals & Chemical Industries 39
Medicure Inc. 40
Clinical Trial Overview of Medicure Inc. 40
Ischemix 41
Clinical Trial Overview of Ischemix 41
Clinical Trial Overview of Top Institutes / Government 42
Radboud University 42
Clinical Trial Overview of Radboud University 42
Medical University of Vienna 43
Clinical Trial Overview of Medical University of Vienna 43
Xijing Hospital 44
Clinical Trial Overview of Xijing Hospital 44
Chang Gung Memorial Foundation 45
Clinical Trial Overview of Chang Gung Memorial Foundation 45
Hospices Civils de Lyon 46
Clinical Trial Overview of Hospices Civils de Lyon 46
Hull and East Yorkshire Hospitals NHS Trust 47
Clinical Trial Overview of Hull and East Yorkshire Hospitals NHS Trust 47
Istituto Clinico Humanitas 48
Clinical Trial Overview of Istituto Clinico Humanitas 48
Karolinska Institute 49
Clinical Trial Overview of Karolinska Institute 49
Ludwig Maximilians Universitat Munich 50
Clinical Trial Overview of Ludwig Maximilians Universitat Munich 50
Regina Elena Cancer Institute 51
Clinical Trial Overview of Regina Elena Cancer Institute 51
Five Key Clinical Profiles 52
Appendix 84
Abbreviations 84
Definitions 84
Research Methodology 85
Secondary Research 85
About GlobalData 86
Contact Us 86
Disclaimer 86
Source 86

List of Tables
Reperfusion Injury Therapeutics, Global, Clinical Trials by Region, 2015* 7
Reperfusion Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Reperfusion Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Reperfusion Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Reperfusion Injury Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Reperfusion Injury Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Reperfusion Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Proportion of Reperfusion Injury to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 14
Reperfusion Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Reperfusion Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Reperfusion Injury to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 17
Reperfusion Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Reperfusion Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Reperfusion Injury Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Reperfusion Injury Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Reperfusion Injury Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Reperfusion Injury Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Reperfusion Injury Therapeutics, Global, Suspended Clinical Trials, 2015* 24
Reperfusion Injury Therapeutics, Global, Withdrawn Clinical Trials, 2015* 25
Reperfusion Injury Therapeutics, Global, Terminated Clinical Trials, 2015* 26
Reperfusion Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Reperfusion Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 28
Reperfusion Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Reperfusion Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Reperfusion Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Ikaria Holdings, Inc., 2015* 32
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Stealth Peptides Inc., 2015* 33
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Y's Therapeutics Co., Ltd., 2015* 34
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Trophos SA, 2015* 35
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2015* 36
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Prolong Pharmaceuticals, 2015* 37
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by NeuroVive Pharmaceutical AB, 2015* 38
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Minapharm Pharmaceuticals & Chemical Industries, 2015* 39
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Medicure Inc., 2015* 40
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Ischemix, 2015* 41
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Radboud University, 2015* 42
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2015* 43
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Xijing Hospital, 2015* 44
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Chang Gung Memorial Foundation, 2015* 45
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospices Civils de Lyon, 2015* 46
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Hull and East Yorkshire Hospitals NHS Trust, 2015* 47
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Istituto Clinico Humanitas, 2015* 48
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Karolinska Institute, 2015* 49
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Ludwig Maximilians Universitat Munich, 2015* 50
Reperfusion Injury Therapeutics Clinical Trials Market, Global, Clinical Trials by Regina Elena Cancer Institute, 2015* 51

List of Figures
Reperfusion Injury Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Reperfusion Injury Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Reperfusion Injury Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Reperfusion Injury Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Reperfusion Injury Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Reperfusion Injury Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Reperfusion Injury Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Proportion of Reperfusion Injury to Cardiovascular Clinical Trials, G7 Countries (%), 2015* 14
Reperfusion Injury Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Reperfusion Injury Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Reperfusion Injury to Cardiovascular Clinical Trials, E7 Countries (%), 2015* 17
Reperfusion Injury Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Reperfusion Injury Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Reperfusion Injury Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Reperfusion Injury Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Reperfusion Injury Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Reperfusion Injury Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Reperfusion Injury Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 27
Reperfusion Injury Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 28
Reperfusion Injury Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 29
Reperfusion Injury Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 30
Reperfusion Injury Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 31
GlobalData Methodology 85

【レポートのキーワード】

再潅流傷害(Reperfusion Injury)、治験、臨床試験、治験、治療薬

★調査レポート[再潅流傷害(Reperfusion Injury):世界の治験レビュー(2015年上半期版)] (コード:GDHC2605CTIDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[再潅流傷害(Reperfusion Injury):世界の治験レビュー(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆